

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Breast Cancer Research Program (BCRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 1 and 2</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPBTA12</p>	<p>Applications naming post-doctoral fellows are encouraged.</p> <p>Each investigator may be named as a Principal Investigator (PI) or Initiating PI on one application and as Partnering PI on one additional application for Breakthrough Award Levels 1 and 2 funding opportunity</p>	<ul style="list-style-type: none"> • Supports promising research with high potential to lead to or make breakthroughs in breast cancer. • Research must have the potential for a major impact and accelerate progress toward ending breast cancer. • Partnering PI Option: Supports meaningful and productive partnerships between two PIs. <p>The following are general descriptions of the research scope for each funding level:</p> <ul style="list-style-type: none"> • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. This level does not require preliminary data. • Funding Level 2: Research already supported by substantial preliminary or published data <i>in breast cancer</i> and strongly validates clinical translation. • Funding Level 2 – Population Science Studies: Studies analyzing human data and biospecimens that meet the above Funding Level 2 qualifications. <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> • Submission of a Letter of Intent is required prior to full application submission. 	<p>Maximum allowable total costs*:</p> <ul style="list-style-type: none"> • Funding Level 1: <ul style="list-style-type: none"> ○ Single PI: \$750,000 ○ Partnering PI Option: \$1.25 million (M) • The maximum period of performance is 3 years. • Funding Level 2: <ul style="list-style-type: none"> ○ Single PI: \$1.65M ○ Partnering PI Option: \$2.50M • The maximum period of performance is 3 years. • Funding Level 2- Population Science Studies: <ul style="list-style-type: none"> ○ Single PI: \$2.50M ○ Partnering PI Option: \$3.35M • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: July 8, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Research Extension Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPCREA</p>	<p>Independent investigators</p> <p>Each investigator may be named as a PI, Initiating PI, or Partnering PI on a single application for this Clinical Research Extension Award funding opportunity.</p>	<ul style="list-style-type: none"> Supports projects entailing a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial or study. Proposed research may be hypothesis-testing or generating or may be designed to generate experimental platforms. Projects proposing initiation of new clinical trials or studies or increasing enrollment in existing studies do not meet the intent. Partnering PI Option: Supports meaningful and productive partnerships between two PIs. <p>Additional Elements</p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Applications must include two or more breast cancer consumer advocates on the research team. 	<ul style="list-style-type: none"> Maximum allowable total costs*: <ul style="list-style-type: none"> Single PI: \$7.0M Partnering PI Option: \$8.4M The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: July 8, 2026 11:59 p.m. Eastern time</p>
<p>Era of Hope Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPEOHS</p>	<p>Independent, non-mentored investigators within six years of their last training position as of the application submission deadline (excluding time spent on family medical leave).</p> <p>Postdoctoral fellows, clinical fellows (including residents and interns) and other researchers currently in training positions are not eligible.</p>	<ul style="list-style-type: none"> Supports exceptionally talented early career scientists that are the “best and brightest” in their field(s) and exhibit extraordinary creativity, vision, innovation and productivity. PIs must demonstrate experience in forming effective partnerships and collaborations and a potential for future leadership in breast cancer research. Applications should articulate a vision that challenges current dogma and looks beyond tradition and convention. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort to conduct breast cancer research under this award. <p>Additional Elements</p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Applications must include two or more breast cancer consumer advocates on the research team. 	<ul style="list-style-type: none"> Maximum allowable total costs*: \$4.9M The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: July 8, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Level 3</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPBTA3</p>	<p>Independent Investigators</p>	<ul style="list-style-type: none"> Supports advanced translational studies and research with high potential to lead to or make breakthroughs in breast cancer. The near-term or long-term impact must move beyond a minor advancement and have the potential to lead to a fundamentally new strategy or approach for preventing or ending breast cancer that is significantly more effective than current strategies or approaches. Small-scale clinical trials are allowed but not required Partnering PI Option: Supports meaningful and productive partnerships between two PIs. <p>Additional Elements</p> <ul style="list-style-type: none"> Pre-application submission is required; application submission is by invitation only. Applications must include two or more breast cancer consumer advocates on the research team. 	<ul style="list-style-type: none"> Maximum allowable total costs*: <ul style="list-style-type: none"> Single PI: \$5.6M Partnering PI Option: \$7.0M The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal) June 12, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>
<p>Breakthrough Award Level 4</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPBTA4</p>	<p>Independent Investigators</p>	<ul style="list-style-type: none"> Supports large-scale projects, including comparative effectiveness trials, that will transform and revolutionize the clinical management of and/or the prevention of breast cancer. Clinical trials are required. PIs should have experience in successfully leading large-scale projects and demonstrated ability to implement a clinical trial. Partnering PI Option: Supports meaningful and productive partnerships between two PIs. <p>Additional Elements</p> <ul style="list-style-type: none"> Pre-application submission is required; application submission is by invitation only. Applications must include two or more breast cancer consumer advocates on the research team. 	<ul style="list-style-type: none"> Maximum allowable total costs*: <ul style="list-style-type: none"> Single PI: \$21.0M Partnering PI Option: \$21.0M The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal) June 12, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Transformative Breast Cancer Consortium Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPTBCCDA</p>	<p>Associate Professor or above</p> <p><i>Investigators named as Consortium Director on a pre-application or full application submitted under funding opportunity HT942526BCRPTBCC A are not eligible.</i></p>	<ul style="list-style-type: none"> Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. PIs are required to include breast cancer advocate(s) on the research team. 	<ul style="list-style-type: none"> Maximum total costs*: \$140,000 The maximum period of performance is 1 year. 	<p>Pre-Application (Letter of Intent): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: July 8, 2026 11:59 p.m. Eastern time</p>
<p>Transformative Breast Cancer Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526BCRPTBCCA</p>	<p>Associate Professor or above</p> <p>The Consortium Director must commit and maintain a minimum level of time and effort of 25% during the period of performance to direct and manage the consortium and to lead their own project team.</p> <p><i>Investigators named as the PI on a pre-application or full application submitted under funding opportunity HT942526BCRPTBCC DA are not eligible to apply as Consortium Director under this funding opportunity.</i></p>	<ul style="list-style-type: none"> Supports synergistic, highly integrated, multidisciplinary and multi-institutional consortia that will address a major problem in a way that a single investigator or group could not accomplish. Allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs; each project team must include at least one breast cancer consumer advocate. The consortium must integrate each team's work so that every component is working toward the consortium's central hypothesis. Applications must propose innovative, paradigm-shifting work, include team members from different disciplines, and include a plan that describes in detail the integration across the consortium in all aspects, including administration, logistics and substance. <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> <i>Pre-application submission is required; application submission is by invitation only.</i> The award mechanism is structured with a Consortium Director and at least three, but not more than four, Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Clinical trials (up to and including phase 1 or equivalent) are allowed but not required. 	<ul style="list-style-type: none"> Maximum allowable total costs*: \$35M The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal) June 12, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.